Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICON9 ovarian cancer maintenance trial of olaparib with or without cediranib
ACTRN12618000498291Phase 3Completed
- Sponsor
- The University of Sydney
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Olaparib + Cediranib with Olaparib (2 arms). Primary endpoint: Progression-free survival. Started Nov 2018; status: completed.
02
Drugs
olaparibcediranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ACTRN12618000498291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000498291.